|Bid||4.21 x 3200|
|Ask||4.58 x 900|
|Day's Range||4.3300 - 4.5900|
|52 Week Range||4.0100 - 12.6000|
|Beta (3Y Monthly)||3.76|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 13, 2019 - Mar 20, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.32|
NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 5.7% in the 12 months ending October 26 […]
Mark Murray became the CEO of Arbutus Biopharma Corporation (NASDAQ:ABUS) in 2008. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Frank Torti has been appointed as Chairman of the Company’s Board of Directors, effective November 26, 2018. “We are pleased to welcome Frank to our Board,” said Dr. Mark J Murray, President and CEO of Arbutus. For much of his career, Dr. Torti was a partner at New Enterprise Associates (NEA), a leading venture capital firm.
- AB-506, a second-generation capsid inhibitor, advanced to HBV patient portion of Phase 1a/1b clinical trial - ONPATTRO™ (patisiran) approved by the U.S. Food and Drug.
WARMINSTER, Pa., Oct. 31, 2018 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that.
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that James Meyers and Myrtle Potter have been appointed to the Arbutus Board of Directors, effective October 18, 2018, replacing Herbert Conrad and Dr. William Symonds. Dr. Symonds will remain with Arbutus as Chairman of its Clinical Advisory Board.
NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
If you’re interested in Arbutus Biopharma Corporation (NASDAQ:ABUS), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...
Arbutus Biopharma (ABUS) provides updates on its HBV development programs. However, uncertainty and early to mid-stage of development remains a concern.
NEW YORK, NY / ACCESSWIRE / October 10, 2018 / U.S. equities finished mostly lower on Tuesday as interest rate increases and rising bond yields continued to put pressure on stocks. The Dow Jones Industrial ...
Today, Arbutus Biopharma (ABUS) stock is trading at $6.87, which is a 24.42% decline from its October 8 closing price of $9.09. Arbutus Biopharma’s closing price on October 8 represents ~111.0% growth from its 52-week low of $4.30 on December 15, 2017. On August 2, Arbutus Pharma hit its 52-week high of $12.60.
AB-506, the Company’s second generation capsid inhibitor, has progressed through the healthy volunteer portion of a multi-component phase 1a/1b study in which it was demonstrated to be generally safe and well-tolerated after 10 days of dosing. This month, AB-506 will enter the 28-day HBV patient portion of the trial, where it will be evaluated both with and without a nucleoside analog.
WARMINSTER, Pa., Oct. 02, 2018 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that.
On September 13, Dicerna Pharmaceuticals (DRNA) stock rose 7.71% to $16.62 from its previous day’s close of $15.43. In the trial, Dicerna’s lead drug candidate, DCR-PHXC, showed that it was capable of bringing urinary oxalate levels to a normal or near-normal range in individuals with primary hyperoxaluria type 1 and hyperoxaluria type 2. The company is conducting studies with DCR-PHXC and investigating its potential as a therapy for all forms of hyperoxaluria.
Today, Arrowhead Pharmaceuticals (ARWR) stock is trading at $20.12, which represents ~42.7% growth from yesterday’s close of $14.10. Arrowhead Pharmaceuticals also hit its 52-week high of $22.39 today.
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Arbutus Biopharma Corporation (NASDAQ: ABUS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:30 PM Eastern ...